Evidence-based recommendations on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women.

This guidance replaces NICE technology appraisal guidance 87.

Guidance development process 

How we develop NICE technology appraisal guidance 

Next review date: The guidance on this technology will be considered for review at the same time that NICE technology appraisal guidance 160 and 204 (2008; amended 2010) are considered for review. The guidance on these technologies will be considered for review by the Guidance Executive as soon as the short clinical guideline on risk assessment has been published.

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

  • National Institute for Health and Care Excellence (NICE) accreditation logo